Clinical Trial Detail

NCT ID NCT03906331
Title Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Recruitment Available
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors Loxo Oncology, Inc.
Indications

Advanced Solid Tumor

Therapies

Selpercatinib

Age Groups: child senior adult

Additional content available in CKB BOOST